Pharm
Posaconazole
search
Posaconazole
, Noxafil
See also
Antifungal Medication
Topical Antifungal
Fluconazole
Isavuconazole
Itraconazole
Voriconazole
Indications
Conditions
Prevention of Invasive
Aspergillus
or Candida
Oropharyngeal
Candidiasis
(including resistant to
Itraconazole
or
Fluconazole
)
Invasive pulmonary
Aspergillosis
(off-label)
Activity (similar activity to
Voriconazole
)
Aspergillus
species
Blastomyces dermatitidis
Candida (most species, including
Fluconazole
resistant strains)
Coccidioides immitis
Cryptococcus neoformans
Dermatophytes or
Tinea
(Microsporum, Epidermophyton, Trichophyton)
Histoplasma capsulatum
Scedosporium apiospermum
Mucorales or Zygomycetes (e.g. Mucor species, Rhizopus species)
Other azoles (including
Voriconazole
) have no significant activity against Mucorales
Contraindications
See
Drug Interaction
s below
Age <13 years
Posaconazole Intravenous formulation if GFR <50 ml
Resistant organisms
Fusarium (variable activity)
Mechanism
Azole Antifungal
Second generation triazole
Structurally similar to
Itraconazole
Inhibits fungal
CYP450
enzymes
Inhibits fungal sterol demethylation (selectively and strongly at 14-alpha demethylase)
Blocks the synthesis of plasma membrane steroids (conversion from lanosterol to ergosterol)
Results in plasma membrane damage
Medications
Oral Delayed Release Tablets: 100 mg
Take with food
Do not split, crush or chew
Oral Suspension: 40 mg/ml
Take within 20 minutes of a meal
Intravenous formulation: 300 mg/16.7 ml vials
First dose may be administered by peripheral IV ove 30 minutes
Subsequent doses should be via
Central Line
or
PICC Line
Posaconazole's IV vehicle may accumulate in renal
Impairment
(GFR<50 ml/min)
Dosing
Adults (and children age >13 years)
Prevention of Invasive
Aspergillus
or Candida
Continued during period of severe
Neutropenia
or
Immunosuppression
Suspension
Take 200 mg (5 ml) of suspension orally three times daily
Delayed-Release Tablets
Load 300 mg orally twice daily for first day
Next, Take 300 mg orally daily
Injection
Load 300 mg IV over 30 to 90 minutes (peripheral, PICC or
Central Line
) every 12 hours for first day
Next, infuse 300 mg IV over 90 minutes via
Central Line
or PICC every 24 hours
Oropharyngeal
Candidiasis
Load suspension 100 mg (2.5 ml) orally within 20 minutes of a meal twice daily on first day
Next, take suspension 100 mg (2.5 ml) orally within 20 minutes of a meal daily for 13 days
Resistant Oropharyngeal
Candidiasis
(refractory to
Itraconazole
or
Fluconazole
, IDSA guidelines)
Load suspension 400 mg (10 ml) orally within 20 minutes of a meal twice daily for 3 days
Next, take suspension 400 mg (10 ml) orally within 20 minutes of a meal daily for up to 28 days
Invasive pulmonary
Aspergillosis
(off-label, in adults)
Take 200 mg (5 ml) suspension orally four times daily until stable
Next, take 400 mg (10 ml) suspension orally twice daily for at least 6 to 12 weeks
Continued throughout
Immunosuppression
and until lesions resolve
Adverse Effects
Common
Nausea
or
Vomiting
Abdominal Pain
Diarrhea
Headache
Fatigue
Uncommon
Fever
Rash
Dry Skin
Taste Dysfunction
(
Dysgeusia
)
Dizziness
Paresthesia
s
Flushing
Serious (rare)
QTc Prolongation
(
Torsades de Pointes
risk)
Toxic Epidermal Necrolysis
Angioedema
Anaphylaxis
Hematologic
Case reports when combined with
Cyclosporine
or
Tacrolimus
in
Transplant Rejection
Hemolytic Uremic Syndrome
Thrombotic Thrombocytopenic Purpura
Safety
Avoid in
Lactation
Pregnancy
Avoid in first trimester
Skeletal malformations have been seen in animal studies
Unknown safety after first trimester
Pharmacokinetics
Oral
Bioavailability
Significantly increased absorption and drug levels (up to 4 fold) when taken with a fatty meal
Alternatives if meals (including
Nutritional Supplement
s) are not tolerated
Take with a carbonated beverage (e.g.
Ginger
ale)
Switch to delayed release tablet
Elimination Half-Life
: 20 to 66 hours
Oral suspension levels >800 mg/day are unlikely to offer any additional benefit
Protein
Binding: High
Metabolism
UDP
Glucuronidation
P-gp
Substrate and Inhibitor
CYP3A4
Inhibitor (strong)
Excretion
Stool
: 71%
Urine: 13%
Drug Interactions
Agents that prolong
QTc Interval
(risk of
Torsades de Pointes
)
See
Prolonged QT Interval due to Medication
Avoid
CYP3A4
substrates that prolong
QTc Interval
Pimozide
Quinidine
Agents that decrease oral suspension absorption (not delayed release tablets)
Cimetidine
Other
H2 Blocker
s and
Antacid
s do not appear affected
Proton Pump Inhibitor
s
Metoclopramide
Other drugs that decrease Posaconazole levels
Efavirenz
Fosamprenavir
Rifabutin
Phenytoin
Posaconazole increases other drug levels
Posaconazole is a strong
CYP3A4
Inhibitor
Atazanavir
Benzodiazepine
s
Alprazolam
Midazolam
Triazolam
Cyclosporine
Decrease
Cyclosporine
doses by 25% and monitor levels
Phenytoin
Rifabutin
Ritonavir
Sirolimus
Tacrolimus
Decrease
Tacrolimus
doses by 66% and monitor levels
Vinca Alkaloid
s
Consider decreasing
Vinca Alkaloid
dose (or avoiding coadministration)
Other drugs that are contraindicated with Posaconazole
Ergot Alkaloids
Halofantrine
Statin
s
Atorvastatin
Lovastatin
Simvastatin
Monitoring
Therapeutic drug levels
Especially consider if severe
Vomiting
,
Diarrhea
or medication delivery by
NG tube
Resources
Posaconazole Tablet (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84
Posaconazole Suspension (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282ddea7-47d8-44e4-8806-169d7cafa951
Posaconazole Delayed Release Tablet (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94a9b028-a2bc-4f41-884d-2d6c536881fc
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
(2012) Med Lett Drugs Ther 10(120): 61-8 [PubMed]
(2006) Med Lett Drugs Ther 48(1248): 93-6 [PubMed]
Type your search phrase here